Literature DB >> 11224419

Contribution of individual differences to discriminative stimulus, antinociceptive and rate-decreasing effects of opioids: importance of the drug's relative intrinsic efficacy at the mu receptor.

D. Morgan1, M.J. Picker.   

Abstract

Rats were trained to discriminate 3.0mg/kg morphine from water in a standard two-lever drug discrimination procedure and tested in a hot water tail-withdrawal procedure. When tested with morphine, fentanyl, buprenorphine and butorphanol, individual animals showed a three- to ten-fold difference in the lowest dose that substituted completely for morphine, whereas 30- to 1000-fold differences were obtained with nalbuphine and levallorphan, respectively. Across repeated determinations, the dose-effect curves for morphine and nalbuphine remained relatively stable within an individual, suggesting that the profound individual differences with nalbuphine were not a consequence of variability in the dose-effect curve. In addition, despite the extremely shallow group dose-effect curves obtained with nalbuphine and levallorphan, intermediate levels of drug-appropriate responding were not evidenced in individual animals. In the tail withdrawal procedure, the doses of morphine and fentanyl required to produce the maximal levels of antinociception varied by approximately three-fold across individual rats. With butorphanol and nalbuphine, differences across animals were greater than 30-fold and 300-fold, respectively, whereas with levallorphan, substantial individual differences were observed in the maximal level of antinociception. Further analyses indicated that animals sensitive to the stimulus effects of nalbuphine and levallorphan were also sensitive to the antinociceptive effects of nalbuphine, levallorphan and butorphanol. In contrast to the individual differences obtained with the stimulus and antinociceptive effects of these opioids, the potency of these drugs for decreasing rate of responding was similar across animals. These findings indicate that the relative efficacy of an opioid at the mu receptor is an important determinant of individual differences in responsiveness to its stimulus and antinociceptive effects, but not to its rate-decreasing effects.

Entities:  

Year:  1996        PMID: 11224419

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  10 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

2.  Role of agonist efficacy in exposure-induced enhancement of mu opioid reward in rats.

Authors:  Megan J Moerke; S Stevens Negus
Journal:  Neuropharmacology       Date:  2019-03-14       Impact factor: 5.250

3.  Exercise reverses pain-related weight asymmetry and differentially modulates trabecular bone microarchitecture in a rat model of osteoarthritis.

Authors:  Jim Cormier; Katherine Cone; Janell Lanpher; Abigail Kinens; Terry Henderson; Lucy Liaw; Edward J Bilsky; Tamara King; Clifford J Rosen; Glenn W Stevenson
Journal:  Life Sci       Date:  2017-05-11       Impact factor: 5.037

4.  Antinociceptive actions of peripheral glucose administration.

Authors:  Rinah T Yamamoto; Wendy Foulds-Mathes; Robin B Kanarek
Journal:  Pharmacol Biochem Behav       Date:  2013-12-10       Impact factor: 3.533

5.  Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.

Authors:  Ahmad A Altarifi; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2014-11-18       Impact factor: 4.030

6.  Opiate states of memory: receptor mechanisms.

Authors:  L A Bruins Slot; F C Colpaert
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

7.  Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.

Authors:  Kathryn L Schwienteck; Kaycee E Faunce; Kenner C Rice; Samuel Obeng; Yan Zhang; Bruce E Blough; Travis W Grim; S Stevens Negus; Matthew L Banks
Journal:  Neuropharmacology       Date:  2019-01-18       Impact factor: 5.250

8.  Concurrent Assessment of the Antinociceptive and Behaviorally Disruptive Effects of Opioids in Squirrel Monkeys.

Authors:  Sarah L Withey; Carol A Paronis; Jack Bergman
Journal:  J Pain       Date:  2018-03-02       Impact factor: 5.820

9.  Acute pain-related depression of operant responding maintained by social interaction or food in male and female rats.

Authors:  A N Baldwin; M L Banks; S A Marsh; E A Townsend; M Venniro; Y Shaham; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2022-01-19       Impact factor: 4.530

Review 10.  Early Life Stress and Risks for Opioid Misuse: Review of Data Supporting Neurobiological Underpinnings.

Authors:  Lynn M Oswald; Kelly E Dunn; David A Seminowicz; Carla L Storr
Journal:  J Pers Med       Date:  2021-04-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.